KNSA
HEALTHCAREKiniksa Pharmaceuticals International plc. - Class A
Live · NASDAQ · May 9, Close
What's Moving KNSA Today?
No stock-specific AI insight has been generated for KNSA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$58.23
Fundamentals
Trading
KNSA News
21 articles- Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue GuidanceYahoo Finance·May 2, 2026
- Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial ResultsYahoo Finance·May 1, 2026
- Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earnings Call Highlights: Robust ...Yahoo Finance·Apr 29, 2026
- Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher TodayThe Motley Fool·Apr 28, 2026
- Kiniksa Pharmaceuticals International Q1 Earnings Call HighlightsMarketbeat·Apr 28, 2026
- Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·Apr 28, 2026
- Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio ExecutionYahoo Finance·Apr 28, 2026
- High Growth Tech Stocks To Watch In The US This April 2026Yahoo Finance·Apr 27, 2026
- Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026Yahoo Finance·Apr 23, 2026
- Kiniksa’s Heart’s Home Campaign Puts ARCALYST Growth Prospects In FocusYahoo Finance·Apr 9, 2026
- Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent PericarditisYahoo Finance·Apr 8, 2026
- Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall MarketYahoo Finance·Apr 6, 2026
- Dow Jones Futures: Leading Stocks Stand Tall As Market Bounces; Look For This Bullish SignalYahoo Finance·Apr 5, 2026
- AI-Fueled Trio Leads 5 Stocks To Watch Near Buy PointsYahoo Finance·Apr 4, 2026
- Exploring High Growth Tech Stocks In The US Market March 2026Yahoo Finance·Mar 27, 2026
- Tarsus Pharmaceuticals Stock Earns Upgrade To RS RatingYahoo Finance·Mar 26, 2026
- Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price PullbackYahoo Finance·Mar 19, 2026
- Evommune Stock Sees RS Rating Rise To 91Yahoo Finance·Mar 18, 2026
- KalVista Pharmaceuticals Stock Sees RS Rating Jump To 86Yahoo Finance·Mar 11, 2026
- Viking Therapeutics Stock Gets RS Rating UpgradeYahoo Finance·Mar 10, 2026
- Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77Yahoo Finance·Mar 4, 2026
All 21 articles loaded
Price Data
52-Week Range
$58.23
Fundamentals
Trading
About Kiniksa Pharmaceuticals International plc. - Class A
Kiniksa Pharmaceuticals Ltd. (KNSA) is a cutting-edge biopharmaceutical company dedicated to addressing high unmet medical needs through the development of innovative therapies. The company's leading candidate, KPL-404, is a targeted monoclonal antibody aimed at modulating B and T lymphocyte activity, potentially transforming treatment options for autoimmune disorders. Kiniksa's robust pipeline, underscored by ongoing clinical trials and strategic collaborations, positions it for significant growth and expansion within the pharmaceutical landscape. With a focus on scientific innovation and a commitment to redefining treatment paradigms, Kiniksa presents a compelling opportunity for institutional investors seeking exposure in the biopharmaceutical sector.